High cumulative doses are often unnecessary and can have major adverse effects
The isolation of compound E, later known as cortisone, from the adrenal gland in 1949 led to its use for treating many medical conditions; the first randomised controlled trial of its benefit for people with asthma was published in 1956.1 However, adverse effects are associated with cumulative corticosteroid doses, both with long term continuous use of low dose preparations and with repeated short courses of high dose preparations. The introduction in 1970 of inhaled corticosteroids (ICS) revolutionised asthma management, providing anti‐inflammatory benefits with a markedly reduced side effect profile. Yet many people with asthma are less adherent to ICS use as preventive treatment than their health care professionals would wish. As many as 80% of patients do not adhere to preventive therapy as prescribed,2 and both practical and perceptual barriers to adherence have been described.3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Subcommittee on clinical trials in asthma. Controlled trial of effects of cortisone acetate in status asthmaticus: report to the Medical Research Council. Lancet 1956; 271: 803–806.
- 2. Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care 2015; 60: 455–468.
- 3. Lindsay JT, Heaney LG. Nonadherence in difficult asthma: facts, myths, and a time to act. Patient Prefer Adherence 2013; 7: 329–336.
- 4. Hew M, McDonald VM, Bardin PG, et al. Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia. Med J Aust 2020; 213: 316–320.
- 5. Aaron SD, Vandemheen KL, FitzGerald JM, et al. Re‐evaluation of diagnosis in adults with physician‐diagnosed asthma. JAMA 2017; 317: 269–279.
- 6. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline‐defined asthma control be achieved? Am J Respir Crit Care Med 2004; 170: 836–844.
- 7. Eger KAB, Amelink M, Hekking PP, Bel E. Overuse of oral corticosteroids in asthma‐modifiable factors and potential role of biologics. Eur Respir J 2019; 54 (Suppl 63): OA5334.
Christine McDonald has received speaker’s fees (paid to her organisation) from Menarini and Astra Zeneca. Christopher Worsnop has received speaker’s fees from HealthEd, GlaxoSmithKline, AstraZeneca, Cipla, Boehringer Ingelheim, Mundipharma, and Menarini.